Novo Nordisk A/S (NYSE:NVO) Short Interest Update

Novo Nordisk A/S (NYSE:NVO) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 4,930,000 shares, a decrease of 18.5% from the October 31st total of 6,050,000 shares. Based on an average daily volume of 4,790,000 shares, the short-interest ratio is currently 1.0 days.

Novo Nordisk A/S Stock Performance

NVO traded up $0.67 during trading on Friday, reaching $106.80. 2,775,149 shares of the company were exchanged, compared to its average volume of 4,509,884. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The stock has a market cap of $479.27 billion, a P/E ratio of 34.56, a PEG ratio of 1.37 and a beta of 0.42. The firm has a 50 day moving average of $112.81 and a 200 day moving average of $128.00. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Natixis Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Zions Bancorporation N.A. lifted its holdings in shares of Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after buying an additional 6,726 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after buying an additional 37,346 shares during the period. Private Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 155.1% in the third quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock valued at $3,953,000 after buying an additional 20,188 shares during the period. Finally, Buckingham Capital Management Inc. acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at $3,874,000. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.